Apollomics Inc. (NASDAQ:APLM) Short Interest Update

Apollomics Inc. (NASDAQ:APLM) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,144 shares, an increase of 104.5% from the June 15th total of 2,515 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 21,851 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Apollomics presently has a consensus rating of “Sell”.

Apollomics Price Performance

APLM opened at $16.91 on Wednesday. Apollomics has a 1 year low of $3.66 and a 1 year high of $42.12. The stock has a fifty day moving average price of $16.20 and a 200 day moving average price of $17.55.

Institutional Investors Weigh In On Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.